.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Dow
Deloitte
Mallinckrodt
Boehringer Ingelheim
UBS
McKesson
US Department of Justice
Harvard Business School
Novartis

Generated: November 20, 2017

DrugPatentWatch Database Preview

NEOSTIGMINE METHYLSULFATE Drug Profile

« Back to Dashboard

What is the patent landscape for Neostigmine Methylsulfate, and when can generic versions of Neostigmine Methylsulfate launch?

Neostigmine Methylsulfate is a drug marketed by Par Sterile Products, Fresenius Kabi Usa, Amphastar Pharms Inc, and Eurohlth Intl Sarl. and is included in four NDAs.

The generic ingredient in NEOSTIGMINE METHYLSULFATE is neostigmine methylsulfate. There are six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.

Pharmacology for NEOSTIGMINE METHYLSULFATE

Medical Subject Heading (MeSH) Categories for NEOSTIGMINE METHYLSULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Sterile Products
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS208405-001Apr 26, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Eurohlth Intl Sarl
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS207042-001Dec 28, 2015APRXNoNo► Subscribe► Subscribe► Subscribe
Fresenius Kabi Usa
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS203629-002Jan 8, 2015RXNoNo► Subscribe► Subscribe► Subscribe
Eurohlth Intl Sarl
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS207042-002Dec 28, 2015APRXNoNo► Subscribe► Subscribe► Subscribe
Par Sterile Products
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS208405-002Apr 26, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Fresenius Kabi Usa
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS203629-001Jan 8, 2015RXNoNo► Subscribe► Subscribe► Subscribe
Amphastar Pharms Inc
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS209933-002Sep 25, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Amphastar Pharms Inc
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate
SOLUTION;INTRAVENOUS209933-001Sep 25, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Moodys
Daiichi Sankyo
McKinsey
US Department of Justice
Novartis
Cerilliant
McKesson
Federal Trade Commission
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot